AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14583369 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 90
Study 14583369 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 90
Study 11080722 — intervention group
Group type: EXPERIMENTAL
Intervention: Open food challenge followed by double-blind placebo-controlled food challenges (DBPCFCs)
Number of subjects: 53
Study 11080722 — intervention group
Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 53
Study 11080722 — intervention group
Group type: COMPARATOR
Intervention: Specific IgE measurement
Number of subjects: 53
Study 11080722 — intervention group
Group type: EXPERIMENTAL
Intervention: DBPCFC
Number of subjects: 53
Study 8664034 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B (daily oral treatment with 30 mg of TAM and 600 mg of FT)
Number of subjects: 525
Study 8664034 — intervention group
Group type: COMPARATOR
Intervention: Regimen A (daily oral treatment with 30 mg of TAM)
Number of subjects: 525
Study 8664034 — intervention group
Group type: COMPARATOR
Intervention: Regimen C (daily oral treatment with 30 mg of TAM and 3 g of PSK)
Number of subjects: 525
Study 8664034 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen D (daily oral treatment with 600 mg of FT)
Number of subjects: 525
Study 8664034 — intervention group
Group type: COMPARATOR
Intervention: Regimen E (daily oral treatment with 3 g of PSK)
Number of subjects: 525
Study 2071654 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral frame with axial micromovement
Number of subjects: 80
Study 2071654 — intervention group
Group type: COMPARATOR
Intervention: Unilateral frame in fixed mode
Number of subjects: 80
Study 6847424 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 100 mg daily
Number of subjects: 21
Study 6847424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31345092 — intervention group
Group type: EXPERIMENTAL
Intervention: USM-guided group
Number of subjects: 136
Study 31345092 — intervention group
Group type: COMPARATOR
Intervention: CFM-guided group
Number of subjects: 136
Study 27555486 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid administration (Group S, n=48) with 10 mL 0.25% bupivacaine + 40 mg methylprednisolone.
Number of subjects: 98
Study 27555486 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar epidural local anesthetic administration (Group L, n=50) with 10 mL 0.25% bupivacaine.
Number of subjects: 98
Study 26602290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin‐fortified formula milk group (FG, containing lactoferrin 38 mg/100 g milk)
Number of subjects: 260
Study 26602290 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed group (BG)
Number of subjects: 260
Study 26602290 — intervention group
Group type: COMPARATOR
Intervention: No lactoferrin‐fortified milk (control group, CG)
Number of subjects: 260
Study 26602290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin‐fortified formula milk group (FG)
Number of subjects: 260
Study 24433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (methotrexate/ciclosporin/prednisolone)
Number of subjects: 431
Study 24433430 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (methotrexate)
Number of subjects: 431
Study 24433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 431
Study 24433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 431
Study 24433430 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 431
Study 23109642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined procedure (trapezius transfer + teres major transfer)
Number of subjects: 35
Study 23109642 — intervention group
Group type: COMPARATOR
Intervention: Single procedure (teres major transfer in isolation)
Number of subjects: 35
Study 23109642 — intervention group
Group type: COMPARATOR
Intervention: Group 2a (deltoid power < M3)
Number of subjects: 35
Study 23109642 — intervention group
Group type: COMPARATOR
Intervention: Group 2b (deltoid power ≥ M3)
Number of subjects: 35
Study 19056555 — intervention group
Group type: COMPARATOR
Intervention: Control bar containing 0.3 g beta-glucan from 6.8 g oats
Number of subjects: 21
Study 19056555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar with an additional 0.9 g beta-glucan from 8.0 g barley
Number of subjects: 21
Study 19056555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar with 8 g FOS
Number of subjects: 21
Study 19056555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar with 0.9 g beta-glucan + 8 g FOS
Number of subjects: 21
Study 19056555 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar with 0.9 g beta-glucan
Number of subjects: 21
Study 18158075 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg BID
Number of subjects: 138
Study 18158075 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine QD (titrated targeting FSG < or =5.6 mmol/L)
Number of subjects: 138
Study 15079179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg)
Number of subjects: 49
Study 15079179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (2 mg)
Number of subjects: 49
Study 15079179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and nebulized)
Number of subjects: 49
Study 11586485 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg twice daily for 4 months
Number of subjects: 23
Study 11586485 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 10 mg daily for 4 months
Number of subjects: 23
Study 11586485 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil and simvastatin (both treatments)
Number of subjects: 23
Study 11586485 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil treatment
Number of subjects: 23
Study 11586485 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin treatment
Number of subjects: 23
Study 9884813 — intervention group
Group type: EXPERIMENTAL
Intervention: dyed aqueous nasal spray
Number of subjects: 0
Study 9884813 — intervention group
Group type: COMPARATOR
Intervention: vigorous inhalation while spraying
Number of subjects: 0
Study 9223113 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IL-2 stimulation (7 day culture)
Number of subjects: 0
Study 9223113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine (IL-2 and interferon alpha and gamma) induced antitumor activity
Number of subjects: 0
Study 2667903 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus streptomycin
Number of subjects: 111
Study 2667903 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus rifampin
Number of subjects: 111
Study 913863 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxprenolol every six hours during marathon bowling
Number of subjects: 32
Study 913863 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 40 mg oxprenolol 60 minutes prior to shooting matches
Number of subjects: 32
Study 913863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 32
Study 913863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31359526 — intervention group
Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 0
Study 31359526 — intervention group
Group type: EXPERIMENTAL
Intervention: Critique of trials
Number of subjects: 0
Study 31359526 — intervention group
Group type: EXPERIMENTAL
Intervention: Research strategy
Number of subjects: 0
Study 31201890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Moraxella species
Number of subjects: 413
Study 31201890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Staphylococcus or Corynebacterium species
Number of subjects: 413
Study 31201890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal microbiota dominated by Streptococcus species
Number of subjects: 413
Study 31201890 — intervention group
Group type: EXPERIMENTAL
Intervention: Moraxella catarrhalis (in vitro)
Number of subjects: 413
Study 27612487 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report
Number of subjects: 126
Study 27612487 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner feedback group (n = 54) that received an alarm and a weekly feedback report shared with a friend, family member, or peer
Number of subjects: 126
Study 27612487 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36) that received a pill‐monitoring device with no alarms or feedback
Number of subjects: 126
Study 26083701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpine skiing for 12 weeks (Intervention Group - IG)
Number of subjects: 23
Study 26083701 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 23135345 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 207
Study 23135345 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day with vitamin D
Number of subjects: 207
Study 23135345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 21596994 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 200 mg
Number of subjects: 62
Study 21596994 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin 75 mg
Number of subjects: 62
Study 21596994 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 62
Study 20064186 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 135
Study 20064186 — intervention group
Group type: COMPARATOR
Intervention: Echinacea
Number of subjects: 135
Study 20064186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 16456197 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training at 20% (LOW)
Number of subjects: 112
Study 16456197 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training at 50% (MED)
Number of subjects: 112
Study 16456197 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training at 80% (HIGH)
Number of subjects: 112
Study 16456197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity power training (20%)
Number of subjects: 112
Study 16456197 — intervention group
Group type: COMPARATOR
Intervention: Control group (nontraining)
Number of subjects: 112
Study 15367065 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-interval traumatic writing condition
Number of subjects: 546
Study 15367065 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-interval traumatic writing condition
Number of subjects: 546
Study 15367065 — intervention group
Group type: COMPARATOR
Intervention: Nonemotional writing control condition
Number of subjects: 546
Study 11308064 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention
Number of subjects: 168
Study 11308064 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping intervention (for those attending at least half of the sessions)
Number of subjects: 168
Study 11308064 — intervention group
Group type: COMPARATOR
Intervention: Mutual support control group
Number of subjects: 168
Study 11308064 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 168
Study 9291170 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg daily for 2 days administered every 4 weeks for 24 weeks
Number of subjects: 25
Study 9291170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9291170 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 25
Study 8325063 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 to 60 min after exercise (6 min ergometer cycling) while breathing cold dry (CD) air (temperature = ‐13 degrees C, relative humidity = 0 percent)
Number of subjects: 8
Study 8325063 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 to 60 min after exercise while breathing warm humid (WH) air (temperature = 33 degrees C, relative humidity = 100 percent)
Number of subjects: 8
Study 8325063 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 8325063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold dry (CD) air
Number of subjects: 8
Study 8325063 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humid (WH) air
Number of subjects: 8
Study 3092099 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at 300 mg dosage
Number of subjects: 0
Study 3092099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3092099 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at high dosages (greater than recommended for opioid addiction)
Number of subjects: 0
Study 3092099 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan) at recommended dosages for opioid addiction
Number of subjects: 0
Study 29578578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg every 4 weeks
Number of subjects: 1991
Study 29578578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks
Number of subjects: 1991
Study 29578578 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 1991
Study 27434082 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-s rest interval trial
Number of subjects: 7
Study 27434082 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-s rest interval trial
Number of subjects: 7
Study 27434082 — intervention group
Group type: COMPARATOR
Intervention: 20-s rest interval trial
Number of subjects: 7
Study 24898471 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 609
Study 24898471 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 609
Study 22704676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 95
Study 22704676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 20721705 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet assay
Number of subjects: 48
Study 20721705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sepsis)
Number of subjects: 48
Study 18360782 — intervention group
Group type: EXPERIMENTAL
Intervention: INVOS (Somanetics, IL, USA) 5100C cerebral oximeter
Number of subjects: 6
Study 16115356 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive/soyabean oil long-chain triacylglycerol (LCT)
Number of subjects: 22
Study 16115356 — intervention group
Group type: COMPARATOR
Intervention: Medium-chain triacylglycerol (MCT)/LCT; 50:50 (w)
Number of subjects: 22
Study 16115356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lipid emulsions
Number of subjects: 22
Study 12072761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice applied for the first hour)
Number of subjects: 12
Study 12072761 — intervention group
Group type: COMPARATOR
Intervention: No cryotherapy (ice applied for the second hour)
Number of subjects: 12
Study 10051701 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 12
Study 10051701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9000837 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules (A)
Number of subjects: 18
Study 9000837 — intervention group
Group type: COMPARATOR
Intervention: Drops (B)
Number of subjects: 18
Study 9000837 — intervention group
Group type: COMPARATOR
Intervention: Tablets (C)
Number of subjects: 18
Study 2209296 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sensory retraining
Number of subjects: 25
Study 2209296 — intervention group
Group type: COMPARATOR
Intervention: Sham retraining
Number of subjects: 25
Study 2209296 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent strength and coordination training
Number of subjects: 25
Study 342062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (prophylactic use)
Number of subjects: 63
Study 342062 — intervention group
Group type: COMPARATOR
Intervention: No cimetidine (control group)
Number of subjects: 63
Study 31778862 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, Simulation, and Sharing (KSS) training
Number of subjects: 250
Study 31437289 — intervention group
Group type: EXPERIMENTAL
Intervention: Our Family Journey (OFJ) intervention
Number of subjects: 60
Study 31437289 — intervention group
Group type: COMPARATOR
Intervention: Written dementia caregiving information (control)
Number of subjects: 60
Study 28379796 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD plus transplantation
Number of subjects: 700
Study 28379796 — intervention group
Group type: COMPARATOR
Intervention: RVD alone
Number of subjects: 700
Study 26365444 — intervention group
Group type: EXPERIMENTAL
Intervention: co-supplemented hemp seed and evening primrose oils along with advised Hot nature diet
Number of subjects: 100
Study 26365444 — intervention group
Group type: EXPERIMENTAL
Intervention: co-supplemented oils
Number of subjects: 100
Study 26365444 — intervention group
Group type: COMPARATOR
Intervention: olive oil
Number of subjects: 100
Study 23261129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to lithium/valproate
Number of subjects: 0
Study 23261129 — intervention group
Group type: COMPARATOR
Intervention: Lithium/valproate (control)
Number of subjects: 0
Study 23261129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to lamotrigine
Number of subjects: 0
Study 23261129 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (control)
Number of subjects: 0
Study 23261129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive to mood stabilizers
Number of subjects: 0
Study 23261129 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilizer monotherapy
Number of subjects: 0
Study 21747104 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning and bimonthly performance feedback
Number of subjects: 19
Study 21747104 — intervention group
Group type: COMPARATOR
Intervention: Control group (joint baseline workshop only)
Number of subjects: 19
Study 19562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 0
Study 19562929 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 19562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Female diabetic patients
Number of subjects: 0
Study 19562929 — intervention group
Group type: EXPERIMENTAL
Intervention: Male diabetic patients
Number of subjects: 0
Study 18038496 — intervention group
Group type: EXPERIMENTAL
Intervention: 1310-nm wavelength laser with sapphire contact cooling
Number of subjects: 0
Study 14746738 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 120
Study 14746738 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal explanations
Number of subjects: 120
Study 14746738 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 120
Study 11408333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential presentation in a temporal forced choice paradigm
Number of subjects: 0
Study 11408333 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous presentation with a spatial forced choice paradigm
Number of subjects: 0
Study 9429962 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training programme
Number of subjects: 5
Study 8430713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 to 20 mg)
Number of subjects: 659
Study 8430713 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 to 100 mg)
Number of subjects: 659
Study 3309012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregestimil
Number of subjects: 19
Study 3309012 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 19
Study 29445864 — intervention group
Group type: EXPERIMENTAL
Intervention: Video gaming group (Group A) - 5 hours of playing the laparoscopic video game (Underground) per week for 4 weeks
Number of subjects: 20
Study 29445864 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - Avoid gaming beyond normal frequency for 4 weeks
Number of subjects: 20
Study 29445864 — intervention group
Group type: COMPARATOR
Intervention: Comparison of video gaming group to control group
Number of subjects: 20
Study 27598398 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS evaluation of sedation with propofol‐remifentanil
Number of subjects: 90
Study 27598398 — intervention group
Group type: COMPARATOR
Intervention: Modified observer's assessment of alertness/sedation scale clinical evaluation
Number of subjects: 90
Study 25006070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RAC; 5 mg/kg)
Number of subjects: 1408
Study 25006070 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 1408
Study 25006070 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunologically castrated (IC) pigs
Number of subjects: 1408
Study 25006070 — intervention group
Group type: COMPARATOR
Intervention: Physically castrated (PC) pigs
Number of subjects: 1408
Study 25006070 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC feeding
Number of subjects: 1408
Study 25006070 — intervention group
Group type: COMPARATOR
Intervention: Control-fed pigs
Number of subjects: 1408
Study 25006070 — intervention group
Group type: EXPERIMENTAL
Intervention: IC pigs
Number of subjects: 1408
Study 25006070 — intervention group
Group type: COMPARATOR
Intervention: PC pigs
Number of subjects: 1408
Study 22437659 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic treatment followed by exercise therapy for 2 months
Number of subjects: 96
Study 22437659 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy alone
Number of subjects: 96
Study 20552353 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using Photofrin, HPD, ALA, or Foscan
Number of subjects: 518
Study 20552353 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for laryngeal cancers
Number of subjects: 518
Study 20552353 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) compared to conventional therapies
Number of subjects: 518
Study 18269366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 302
Study 18269366 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302